New hope for tough lung cancer: ALPS12 drug trial begins

NCT ID NCT07107490

Recruiting now Disease control Sponsor: Chugai Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called ALPS12 in people with extensive-stage small cell lung cancer that has returned after prior treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 122 participants will take part across multiple centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Ehime University Hospital
RECRUITING

Tōon, Ehime, 791-0295, Japan
Kindai University Hospital
RECRUITING

Sakai, Osaka, 590-0197, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
Niigata Cancer Center Hospital
RECRUITING

Niigata, 951-8566, Japan
Queen Mary Hospital
RECRUITING

Hong Kong, Hong Kong
Show Chwan Memorial Hospital
RECRUITING

Changhua, 500, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.